(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) on Monday said it has submitted its AD04 application for consideration under the U.S. Food and Drug Administration Commissioner's National Priority Voucher Pilot Program (CNPV).
The program allows companies to receive an expedited review of a drug application, including closer interaction with the FDA and a rolling review process.
Cary Claiborne, President and Chief Executive Officer of Adial, commented, "As we continue to advance the AD04 program and actively plan for the next phase of our clinical development efforts, we believe the Commissioners National Priority Voucher Pilot Program is an excellent strategic fit for AD04 and aligns well with our ongoing collaboration with the FDA."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
